You might also like
Intuitive Surgical, Inc. develops, manufactures, and markets advanced surgical systems designed to enable minimally invasive care . The company offers the da Vinci® surgical systems and the Ion® endoluminal system, generating revenue from their sale and lease, as well as from recurring sales of instruments, accessories, and services . Intuitive Surgical also provides a portfolio of learning offerings and digital solutions, although these do not currently generate material revenue .
- da Vinci® Surgical Systems - Comprises a surgeon console, a patient-side cart, and a high-performance vision system, facilitating minimally invasive surgeries.
- Ion® Endoluminal System - Includes a system cart, a controller, a catheter, and a vision probe, designed for minimally invasive endoluminal procedures.
- Instruments and Accessories - Offers a range of instruments and accessories with limited lives that require regular replacement, contributing to recurring revenue.
- Service Contracts - Provides service contracts typically entered into at the time of system sale or lease, ensuring ongoing support and maintenance.
- Learning Offerings and Digital Solutions - Delivers a portfolio of educational and digital solutions, although these currently do not generate significant revenue.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
David J. Rosa ExecutiveBoard | President | Board Member at Kardium Inc. | Joined ISRG in 1996; became President in 2023; holds multiple patents in robotic-assisted surgery; M.S. in Mechanical Engineering from Stanford. | |
Gary S. Guthart ExecutiveBoard | CEO | Board Member at Illumina, Inc. | Joined ISRG in 1996; became CEO in 2010; instrumental in advancing robotic-assisted surgery; holds a Ph.D. in Engineering Science from Caltech. | View Report → |
Bob DeSantis Executive | EVP, Chief Strategy and Corporate Operations Officer | None | Joined ISRG in 2020; oversees corporate strategy and operations; has received significant stock awards for contributions. | |
Gary H. Loeb Executive | SVP, General Counsel, and Chief Compliance Officer | None | Joined ISRG in 2022; oversees legal and compliance matters; previously held senior roles at Genentech and Mammoth Biosciences; J.D. from Columbia Law School. | |
Henry L. Charlton Executive | EVP, Chief Commercial and Marketing Officer | None | Joined ISRG in 2003; promoted to EVP in 2025; has led commercial operations in the U.S. and Europe; B.A. in History and English from the University of Pittsburgh. | |
Jamie E. Samath Executive | EVP, CFO, and Head of Business Technology | None | Joined ISRG in 2013; promoted to CFO in 2022 and EVP in 2025; oversees financial and business technology operations; CPA (inactive). | |
Myriam J. Curet Executive | EVP, Chief Medical Officer | Board Member at Nektar Therapeutics, Stereotaxis, Inc., and Inspire Medical Systems, Inc. | Joined ISRG in 2005; oversees clinical and medical affairs; Clinical Professor of Surgery at Stanford; M.D. from Harvard Medical School. | |
Amy L. Ladd Board | Director | Board Member at Allakos, Inc.; Vice President of the Association of Bone and Joint Surgeons | Joined ISRG Board in 2019; Professor of Orthopaedic Surgery at Stanford; M.D. from SUNY Upstate Medical University. | |
Craig H. Barratt Board | Chair of the Board | Chair of the Board at IonQ, Inc.; Board Member at private companies | Joined ISRG Board in 2011; became Chair in 2020; former CEO of Atheros Communications; Ph.D. from Stanford University. | |
Jami Dover Nachtsheim Board | Director | Board Member at Cerus Corp. and Telesis Bio Inc. | Joined ISRG Board in 2017; former Corporate VP at Intel; B.S. in Business Management from Arizona State University. | |
Keith R. Leonard Jr. Board | Director | Chair of the Board at Unity Biotechnology; Board Member at Arcutis Biotherapeutics, Inc. | Joined ISRG Board in 2016; co-founder and former CEO of Kythera Biopharmaceuticals; M.B.A. from UCLA Anderson School of Management. | |
Lewis Chew Board | Director | Chair of the Audit Committee at Cadence Design Systems and Arista Networks | Joined ISRG Board in 2024; former CFO at Dolby Laboratories; B.S. in Accounting from Santa Clara University. | |
Mark J. Rubash Board | Director | Board Member at iRhythm Technologies, Inc.; Board Member at a private company | Joined ISRG Board in 2007; former CFO at Eventbrite and Shutterfly; B.S. in Accounting from California State University Sacramento. | |
Monica P. Reed Board | Director | Founder of Reed Consulting Group | Joined ISRG Board in 2021; extensive experience in healthcare systems; M.D. from Loma Linda University. | |
Sreelakshmi Kolli Board | Director | EVP and Chief Digital Officer at Align Technology; Board Member at Zimmer Biomet Holdings, Inc. | Joined ISRG Board in 2023; recognized for expertise in digital transformation; M.S. in Computer Applications from NIT Trichy, India. |
- Given your expectation for gross margins to be lower next year due to significant incremental depreciation from new facilities, how do you plan to mitigate margin pressures while continuing to invest in R&D and maintain top-tier profitability?
- With the da Vinci 5 rollout prioritizing single-system placements and dual console availability delayed, are you concerned that adoption among larger academic centers will be slower, potentially impacting procedure growth in this segment?
- The percentage of systems placed under usage-based arrangements has increased from 12% to 15%, introducing variability in procedure volumes; how does this shift impact your revenue predictability and what measures are you taking to manage the risk of underutilization?
- In international markets, regulatory approvals are staggered with Korea approved but delays in Japan and Europe not expected until the end of next year; how does this affect your global growth strategy and what plans do you have to accelerate market entry in these key regions?
- As innovation shifts toward software with potentially shorter development cycles, how do you plan to continue differentiating your platform given the ease of replication in software, and what role will hardware innovation play in maintaining your competitive advantage?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
The company faces competition from larger and well-established companies as it adds new robotically controlled products, such as stapling and energy products, that compete with offerings traditionally within the domains of open surgery and/or conventional minimally invasive surgery. | |
The company faces competition from larger and well-established companies as it adds new robotically controlled products, such as stapling and energy products, that compete with offerings traditionally within the domains of open surgery and/or conventional minimally invasive surgery. | |
Beijing Surgerii Robotics Company Limited | The company competes with entities that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field. |
CMR Surgical Ltd. | The company competes with entities that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field. |
Distalmotion SA | The company competes with entities that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field. |
Harbin Sizhe Rui Intelligent Medical Equipment Co., Ltd. | The company competes with entities that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field. |
Karl Storz SE & Co. KG | The company competes with entities that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field. |
Medicaroid Corporation | The company competes with entities that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field. |
meerecompany Inc. | The company competes with entities that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field. |
Noah Medical | The company competes with entities that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field. |
Shandong Weigao Group Medical Polymer Company Ltd. | The company competes with entities that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field. |
Shanghai Microport Medbot (Group) Co., Ltd. | The company competes with entities that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field. |
Shenzhen Edge Medical Co., Ltd. | The company competes with entities that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field. |
SS Innovations International, Inc. | The company competes with entities that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
da Vinci and Ion distribution businesses from ab medica, Abex, and Excelencia Robotica | 2025 | Deal Value & Structure: Involves an upfront cash payment of approximately €290 million with an additional €31 million in commercial milestone payments. Strategic Rationale & Capabilities: The acquisition enables Intuitive to establish a direct presence in Italy, Spain, Portugal, Malta, and San Marino, integrating operations into its European organization to deepen customer relationships and expand patient access to minimally invasive care. Key Terms: Announced on January 21, 2025, it is expected to close in the first half of 2026, pending regulatory approvals and customary closing conditions. |
Orpheus Medical Ltd. | 2020 | Deal Value & Structure: Acquired for $38 million (net of cash acquired), with Orpheus Medical becoming a wholly owned subsidiary. Strategic Rationale & Capabilities: The acquisition was driven to deepen and expand Intuitive’s integrated informatics platform by leveraging Orpheus Medical’s expertise in IT connectivity and surgical video processing and archiving for hospitals. |
Recent press releases and 8-K filings for ISRG.
- CEO Change: Dave Rosa, currently President, is promoted to CEO effective July 1, 2025, while current CEO Gary Guthart transitions to Executive Chair, and Board Chair Craig Barratt is named lead independent director.
- Compensation Adjustments: Rosa’s base salary increases from $825K to $925K with a higher bonus target, and Guthart’s base salary decreases from $1.05M to $700K, reflecting the leadership transition details.
- Incentive Award Plan Update: Stockholders approved the amended 2010 Incentive Award Plan, increasing authorized shares from 115,350,000 to 120,350,000 and extending its term to 2035.
- Proxy Vote Outcomes: At the Annual Meeting, stockholders elected eleven directors and approved key executive compensation proposals.
- Share Buyback Program: The Board increased the common stock repurchase authorization to an aggregate of $4.0 billion.
- Strong financial performance: Q1 2025 revenue reached $2.25 billion (up 19% YoY); GAAP net income was $698 million and pro forma EPS of $1.81
- Robust system placements: 367 da Vinci systems placed, expanding the global installed base to 10,189 units (including 147 DV5 and 19 SP systems)
- Strong procedure growth: Overall procedures increased by 17% with day-adjusted growth of 18.5%, reflecting robust market demand
- Updated full-year guidance: Procedure growth guidance raised to 15%-17% and pro forma gross margins adjusted to 65%-66.5%, with tariffs expected to add ~1.7% of revenue costs
- Forward-looking priorities & risks: Emphasis on upcoming product launches and digital tool enhancements while addressing macroeconomic uncertainties and supply challenges